Reason for request
Inclusion
Clinical Benefit
| Substantial |
Substantial actual benefit |
Clinical Added Value
| important |
KALYDECO offers a substantial improvement in actual benefit (IAB II) in the treatment of cystic fibrosis in patients aged 6 years and older with the G551D-CFTR mutation. |
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
ETk9ETKV2ZwRd823
